NEW YORK (AP) - Biotechnology company Gilead Sciences Inc. said Friday its
experimental inhaled cystic fibrosis treatment continued meeting safety goals in
an ongoing late-stage study.
The inhaled version of aztreonam lysine is already under review by the Food
and Drug Administration and Gilead expects a decision by Sept. 16. The most
recent study results are from an open-label, ongoing Phase III clinical trial
involving patients from a prior late-stage study. The goal of the ongoing study
is to further evaluate the safety of patients.
Patients will be followed for an overall treatment period of 18 months and
the study will be complete by the fourth quarter.
Foster City, Calif.-based Gilead presented the most recent study data at the
31st annual European Cystic Fibrosis Conference in Prague, Czech Republic.
Gilead shares rose 99 cents to $53.72 in morning trading.
Copyright 2008 Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten, or redistributed.
|